Unexplored therapeutic opportunities in the human genome

• Published in: Nature reviews. Drug discovery Vol. 17; no. 5; pp. 317 - 332
• Main Authors: Oprea, Tudor I., Bologa, Cristian G., Brunak, Søren, Campbell, Allen, Gan, Gregory N., Gaulton, Anna, Gomez, Shawn M., Guha, Rajarshi, Hersey, Anne, Holmes, Jayme, Jadhav, Ajit, Jensen, Lars Juhl, Johnson, Gary L., Karlson, Anneli, Leach, Andrew R., Ma'ayan, Avi, Malovannaya, Anna, Mani, Subramani, Mathias, Stephen L., McManus, Michael T., Meehan, Terrence F., von Mering, Christian, Muthas, Daniel, Nguyen, Dac-Trung, Overington, John P., Papadatos, George, Qin, Jun, Reich, Christian, Roth, Bryan L., Schürer, Stephan C., Simeonov, Anton, Sklar, Larry A., Southall, Noel, Tomita, Susumu, Tudose, Ilinca, Ursu, Oleg, Vidović, Dušica, Waller, Anna, Westergaard, David, Yang, Jeremy J., Zahoránszky-Köhalmi, Gergely
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.05.2018; Nature Publishing Group
• Subjects: 631/154/555; 631/154/556; 692/308/153; analysis; association; Biomedical research; Biomedicine; Biotechnology; Cancer Research; Cellular proteins; drug discovery; Drug metabolism; druggable genome; expression; genetic; Genetic aspects; Genomes; Knowledge management; large-scale; ligands; Medical Genetics; Medicinal Chemistry; Medicinsk genetik; Molecular Medicine; orphan nuclear receptors; Pharmacological research; Pharmacology/Toxicology; protein-degradation; Proteins; Proteomics; schizophrenia; target identification; Testing
• ISSN: 1474-1776; 1474-1784
• DOI: 10.1038/nrd.2018.14

In 2014, the Illuminating the Druggable Genome programme was launched to promote the exploration of currently understudied but potentially druggable proteins. This article discusses how the systematic collection and processing of a wide array of biological and chemical data as part of this programme has enabled the development of evidence-based criteria for tracking the target development level of human proteins, which indicates a substantial knowledge deficit for approximately one out of three proteins in the human proteome. It also highlights the nature of the unexplored therapeutic opportunities for major protein families. A large proportion of biomedical research and the development of therapeutics is focused on a small fraction of the human genome. In a strategic effort to map the knowledge gaps around proteins encoded by the human genome and to promote the exploration of currently understudied, but potentially druggable, proteins, the US National Institutes of Health launched the Illuminating the Druggable Genome (IDG) initiative in 2014. In this article, we discuss how the systematic collection and processing of a wide array of genomic, proteomic, chemical and disease-related resource data by the IDG Knowledge Management Center have enabled the development of evidence-based criteria for tracking the target development level (TDL) of human proteins, which indicates a substantial knowledge deficit for approximately one out of three proteins in the human proteome. We then present spotlights on the TDL categories as well as key drug target classes, including G protein-coupled receptors, protein kinases and ion channels, which illustrate the nature of the unexplored opportunities for biomedical research and therapeutic development.